Roche

Roche Holding AG Genussscheine (SWX: ROG) is a multinational pharmaceutical company headquartered in Basel, Switzerland. It has operations across more than 150 countries and produces both pharmaceutical and diagnostic solutions for a range of diseases. Fortune ranked Roche as the fifth-largest global pharmaceutical company after Roche generated CHF 62.8 billion in revenue in 2021. In the last ten years, it has made a series of pharmaceutical company acquisitions including Genentech, Flatiron Health, Foundation Medicine, Promedior, Stratos Genomics, Trophos, and Viewics. As of December 2023, the company’s pharmaceutical product pipeline included 52, 20, and 9 drug candidates in Phase I, II, and III stages of clinical trials, respectively. 

Roche has two areas of operations: pharmaceuticals and diagnostics. The pharmaceutical operations generate over 76% of its top-line revenue and offer treatments for areas such as oncology, immunology, neuroscience, hemophilia A, infectious diseases, and ophthalmology. Of these, oncology is the largest subdivision, followed by neuroscience, contributing 43% and 19%, respectively, to the division’s top-line revenue in 2023. Its diagnostics operations mainly include 1) core lab services (55% of segment revenue), which offer diagnostic solutions for clinical chemistry, immunoassays, and custom biotech, and 2) molecular lab services (16% of segment revenue), which offer its diagnostic solutions for identifying and monitoring pathogens, screening donors, sexual health, and genomic studies.

For FY2023, Roche’s largest market was North America, accounting for 48% of its total earned revenue, followed by Asia and Europe at 23% each. Of the 48%, the US alone made up 97%. Within the European market, Germany was the largest contributor (22% of the region's sales).  

The company noted that it was looking to expand its portfolio of medicines and candidates and, as of December 2023, had 82 new molecular entities (NMEs) and additional indications (AIs) across several stages of development. Further, Roche’s Core R&D spend was CHF 13.2 billion (USD 14.7 billion) in 2023 (23% of group revenue).